Single Treatment With FT1050 of an Ex-vivo Modulated Umbilical Cord Blood Unit

Exclusion Criteria

• •1. The following hematologic malignancies are excluded:
• •* Myelofibrosis (Agnogenic Myeloid Metaplasia)
• •* Aplastic anemia.
• •2. Previous treatment that included an allogeneic transplant
• •3. Cardiac disease: symptomatic congestive heart failure or evidence of left ventricular
• •4. dysfunction (Ejection fraction \< 40%) as measured by gated radionucleotide ventriculogram or echocardiogram; active angina pectoris, or uncontrolled hypertension; history of myocardial infarction with depressed ejection fraction.
• •5. Pulmonary disease: symptomatic chronic obstructive lung disease, symptomatic restrictive lung disease, or corrected DLCO of \< 50% of predicted, corrected for hemoglobin.
• •6. Renal disease: serum creatinine \> 2.0 mg/dl and calculated creatinine clearance \< 40 mL/min
• •7. Hepatic disease: serum bilirubin \> 2.0 mg/dl (except in the case of Gilbert's syndrome or ongoing hemolytic anemia), SGOT or SGPT \> 3 x upper limit of normal.
• •8. Neurologic disease: symptomatic leukoencephalopathy, active CNS malignancy or other neuropsychiatric abnormalities believed to preclude transplantation.
• •9. HIV antibody.
• •10. Uncontrolled infection.
• •11. Pregnancy or breast feeding mother.
• •12. Inability to comply with the requirements for care after allogeneic stem cell transplantation.
• •13. Participation in a concurrent clinical trial with a novel, unapproved investigational agent \< 30 days prior to Day 0.